LonS.SmithMD

Oncology • San Antonio, TX

Physician

Join to view full profile

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Smith's full profile

Already have an account?

Office
4383 Medical Dr
Fl 2
San Antonio, TX 78229
Phone+1 210-616-5700

Fax+1 210-593-5997
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1979 - 1982
LSU School of Medicine in ShreveportClass of 1979

Certifications & Licensure

TX State Medical License 1981 - 2024
LA State Medical License 1979 - 1981
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
Amita Patnaik, Erika Hamilton, Yan Xing, Drew W Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, Ai-Min Hui> ;Cancers. 2022 Oct 12
39 citations
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony W. Tolcher, Keith T. Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas E. Witzig, Thomas M. Habermann, Andrea J. Bullock, Edwin P. Rock, Agnes Elekes, Chest...> ;The Oncologist. 2018 Jun 1
561 citations
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik, S. Peter Kang, Drew W. Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Esp...> ;Clinical Cancer Research. 2015 May 14
5 citations
Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.
Leticia Batista Azevedo Rangel, Jodi L. Taraba, Christopher R. Frei, Lon Smith, Gladys Rodriguez, John G. Kuhn> ;Breast Cancer Research and Treatment. 2014 Nov 14
50 citations
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors
Toshio Shimizu, Patricia LoRusso, Kyri Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon Smith, Drew W. Rasco, Theresa Mays, Glenda Chambers, Anna Ma, Jing Wang, Rob...> ;Clinical Cancer Research. 2014 Oct 1
45 citations
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
Tomislav Dragovich, Daniel A. Laheru, Farshid Dayyani, Vanessa Bolejack, Lon Smith, John E. Seng, Howard A. Burris, Peter Rosen, Manuel Hidalgo, Paul S. Ritch, Amanda ...> ;Cancer Chemotherapy and Pharmacology. 2014 Jun 18
59 citations
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Jeffrey R. Infante, Kyriakos P. Papadopoulos, Johanna C. Bendell, Amita Patnaik, Howard A. Burris, Drew W. Rasco, Suzanne F. Jones, Lon Smith, Donna S. Cox, Michael Du...> ;European Journal of Cancer. 2013 Jun 1
337 citations
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew W. Rasco, Lon Smith, Shelly Gunn, Leslie Smetzer, Theresa Mays, Brianne Kaiser, M...> ;Clinical Cancer Research. 2012 Apr 15
811 citations
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Daniel A. Laheru, Lon Smith, T. E. Wood, Ronald L. Korn, Neil P. Desai, Vuong Trieu, Jose Iglesias, Hui Zhan...> ;Journal of Clinical Oncology. 2011 Dec 1
A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression...
Ikdahl T, Davidenko I, Bassi C, Tomasetto E, Smith L, McLachlan S, Jones S, Raponi M, Isaacson J, Voong C, Rolfe L, Allen AR, Poplin E> ;J. Clin. Oncol.. 2011-05-20
Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).
Kurzrock R, Patnaik A, Rosenstein L, Fu S, Papadopoulos KP, Smith DA, Falchook GS, Chambers G, Gauvin JL, Naing A, Smith LS, Gonzalez T, Tsimberidou AM, Mays TA, Cox D...> ;J. Clin. Oncol.. 2011-05-20
Phase II trial of vatalinib in patients with advanced or metastatic pancreatic adenocarcinoma who failed gemcitabine therapy.
Dragovich T, Laheru DA, Crowley JJ, Smith LS, Seng J, Burris HA, Rosen PJ, Von Hoff DD, Bolejack V, Hidalgo M> ;J. Clin. Oncol.. 2008-05-20
21 citations
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
Jordi Rodon, Mitchell Garrison, Lisa A. Hammond, Johann S. de Bono, Lon Smith, Leonardo Forero, Desirée Hao, Chris H. Takimoto, John M. Lambert, Lini Pandite, Maria Ho...> ;Cancer Chemotherapy and Pharmacology. 2008 Feb 27
18 citations
Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy.
J. L. Grabinski, Lon Smith, Gary B. Chisholm, R. Drengler, Gladys Rodriguez, A. S. Lang, S. P. Kalter, A. M. Garner, L. M. Fichtel, J. Hollsten, Bradley H Pollock, Joh...> ;Breast Cancer Research and Treatment. 2006 Jan 1
26 citations
A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms
Lisa A. Hammond, John R. Eckardt, John G. Kuhn, Stanton L. Gerson, Thomas R. Johnson, Lon Smith, Ronald Drengler, Elizabeth Campbell, Geoffrey R. Weiss, Daniel D. Von ...> ;Clinical Cancer Research. 2004 Mar 1
137 citations
Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study
Anthony W. Tolcher, Leonel Ochoa, Lisa A. Hammond, Amita Patnaik, Tam Edwards, Chris H. Takimoto, Lon Smith, Johann S. de Bono, Garry Schwartz, Theresa Mays, Zdenka Lu...> ;Journal of Clinical Oncology. 2003 Jan 15
34 citations
Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel
Manuel Hidalgo, C. Aylesworth, Lisa A. Hammond, Carolyn D. Britten, Geoffrey R. Weiss, J. Stephenson, Garry Schwartz, Amita Patnaik, Lon Smith, Kathleen Molpus, Sally ...> ;Journal of Clinical Oncology. 2001 May 1
67 citations
Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malign...
Eric K. Rowinsky, Rachel Humphrey, Lisa A. Hammond, C. Aylesworth, Leslie Smetzer, Manuel Hidalgo, Mark Morrow, Lon Smith, Allison M. Garner, J. Mel Sorensen, Daniel D...> ;Journal of Clinical Oncology. 2000 Jan 1
80 citations
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
Carolyn D. Britten, Eric K. Rowinsky, Sharyn D. Baker, Geoffrey R. Weiss, Lon Smith, J. Stephenson, Mace L. Rothenberg, L Smetzer, J Cramer, W Collins, D. D. Von Hoff,...> ;Clinical Cancer Research. 2000 Jan 1
55 citations
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
S. Gail Eckhardt, Jinee Rizzo, Kevin R. Sweeney, Gillian F. Cropp, Sharyn D. Baker, Maura Kraynak, John G. Kuhn, Miguel A. Villalona-Calero, Lisa A. Hammond, Geoffrey ...> ;Journal of Clinical Oncology. 1999 Apr 1
15 citations
A phase I study of docetaxel and 5-fluorouraciI in patients with advanced solid malignancies
T. Petit, C. Aylesworth, H. A. Burris, P. Ravdin, G.I Rodriguez, Lon Smith, N. Peacock, Leslie Smetzer, R. Bellet, D. D. Von Hoff, Eric K. Rowinsky> ;Annals of Oncology. 1999 Feb 1
109 citations
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR...
Eric K. Rowinsky, Lon Smith, Yufeng Wang, P Chaturvedi, M Villalona, E. Campbell, C. Aylesworth, S. G. Eckhardt, Lisa A. Hammond, Maura Kraynak, Ronald Drengler, J. St...> ;Journal of Clinical Oncology. 1998 Sep 1
29 citations
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
S. G. Eckhardt, Sharyn D. Baker, John R. Eckardt, T G Burke, D L Warner, J. G. Kuhn, G. I. Rodriguez, Suzanne M. Fields, Allison Thurman, Lon Smith, Mace L. Rothenberg...> ;Clinical Cancer Research. 1998 Mar 1
5 citations
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors
Peacock Nw, H. A. Burris, Dieras, Smith L, G. I. Rodriguez, Eckardt, Suzanne F. Jones, Hardy J, John A. Hohneker, Bigley J, Von Hoff Dd> ;Investigational New Drugs. 1998 Jan 1
29 citations
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
Eric Raymond, H. A. Burris, E. K. Rowinsky, J R Eckardt, G. I. Rodriguez, Lon Smith, Geoffrey R. Weiss, D. D. Von Hoff> ;Annals of Oncology. 1997 Oct 1
Join now to see all